Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given a $18.00 price target by research analysts at Canaccord Genuity in a research note issued to investors on Tuesday. The firm presently has a “buy” rating on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 103.39% from the company’s current price.

A number of other equities analysts also recently weighed in on KPTI. BidaskClub downgraded Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 24th. Jefferies Group LLC reissued a “buy” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, July 14th. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 25th. Finally, Robert W. Baird reissued an “outperform” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $14.26.

Shares of Karyopharm Therapeutics (NASDAQ KPTI) opened at 8.85 on Tuesday. The company has a 50-day moving average price of $9.24 and a 200 day moving average price of $10.07. The stock’s market capitalization is $416.99 million. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 72.41% and a negative net margin of 50,646.40%. The company’s revenue for the quarter was down 95.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.84) EPS. Analysts forecast that Karyopharm Therapeutics will post ($2.69) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Karyopharm Therapeutics Inc. (KPTI) PT Set at $18.00 by Canaccord Genuity” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/08/canaccord-genuity-reiterates-buy-rating-for-karyopharm-therapeutics-inc-nasdaqkpti.html.

Institutional investors have recently bought and sold shares of the stock. Palo Alto Investors LLC increased its position in Karyopharm Therapeutics by 6.4% in the first quarter. Palo Alto Investors LLC now owns 3,406,475 shares of the company’s stock valued at $43,739,000 after buying an additional 206,079 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its position in Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares during the last quarter. State Street Corp increased its position in Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock valued at $3,820,000 after buying an additional 25,015 shares during the last quarter. Wellington Management Group LLP increased its position in Karyopharm Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 5,780,553 shares of the company’s stock valued at $74,223,000 after buying an additional 54,137 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock valued at $2,454,000 after buying an additional 202,714 shares during the last quarter. 57.46% of the stock is currently owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.